Breaking News Instant updates and real-time market news.

ROKU

Roku

$160.41

-1.2 (-0.74%)

, SPLK

Splunk

$149.24

-1.67 (-1.11%)

09:08
12/02/19
12/02
09:08
12/02/19
09:08

Fly Intel: Pre-market Movers

HIGHER: EyeGate (EYEG), up 4% after announcing that it has received additional topline data in its corneal wound repair pivotal study. In the study, EyeGate's Ocular Bandage Gel demonstrated a more rapid corneal wound closure over the standard-of-care as early as day two... Evofem (EVFM), up 24% after announcing results from AMPREVENCE, a Phase 2b clinical trial evaluating the efficacy and safety of Amphora for the prevention of urogenital chlamydia and gonorrhea in women. The study met both its primary and secondary endpoints of reducing the risk of chlamydia and gonorrhea infection, respectively... AeroVironment (AVAV), up 5% after Baird analyst Peter Arment upgraded shares to Outperform from Neutral. The analyst expects solid Q2 results tomorrow and believes the outlook for 2020 should be at least maintained with potential for upside... McDermott (MDR), up 12% after the company and its joint venture partner, Chiyoda International, announced that Train 2 of the Cameron project has reached the final commissioning stage... Splunk (SPLK), up 2% after Goldman Sachs analyst Christopher Merwin upgraded the stock to Buy from Neutral with a price target of $180, up from $147. After a "strong" fiscal Q3 report, the analyst sees "several catalysts" for Splunk shares to positively re-rate over the next 12 months. LOWER: Lexicon (LXRX), down 19% after announcing that the Office of New Drugs of the FDA has reiterated the FDA's prior position and denied the company's appeal of the complete response letter in relation to the new drug application for sotagliflozin in type 1 diabetes... Roku (ROKU), down 7% after Morgan Stanley analyst Benjamin Swinburne downgraded shares to Underweight from Equal Weight with a price target of $110, up from $100. Roku continues to execute a "sound strategy" to capitalize on the shift to streaming, but there are risks to growth expectations not reflected in current valuation levels, Swinburne tells investors... Teladoc (TDOC), down 2% after SunTrust analyst Alexander Draper downgraded the stock to Hold from Buy with an unchanged $80 price target... Aqua Metals (AQMS), down 40% after announcing a fire occurred in the AquaRefining area of its plant. The fire and related intense heat and smoke caused significant damage to a material amount of equipment in the AquaRefinery area, including all 16 AquaRefining modules, control wiring and other supporting infrastructure... ADT Inc. (ADT), down 4% after BofA Merrill Lynch analyst Gary Bisbee downgraded shares to Neutral from Buy with a $9.50 price target. The analyst notes that while the valuation on the stock is "far from demanding" and investment sentiment in the name is still "subdued", he also sees "few catalysts" to warrant sustained outperformance.

ROKU

Roku

$160.41

-1.2 (-0.74%)

SPLK

Splunk

$149.24

-1.67 (-1.11%)

EYEG

EyeGate

$7.83

0.105 (1.36%)

EVFM

Evofem

$6.08

0.02 (0.33%)

AVAV

AeroVironment

$61.39

-0.51 (-0.82%)

MDR

McDermott

$0.80

-0.0069 (-0.86%)

LXRX

Lexicon

$3.54

-0.01 (-0.28%)

TDOC

Teladoc

$83.65

-2.19 (-2.55%)

AQMS

Aqua Metals

$1.34

-0.025 (-1.83%)

ADT

ADT Inc.

$9.25

-0.23 (-2.43%)

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 09

    Dec

ROKU Roku
$160.41

-1.2 (-0.74%)

12/02/19
MSCO
12/02/19
DOWNGRADE
Target $110
MSCO
Underweight
Roku downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne downgraded Roku to Underweight from Equal Weight with a $110 price target.
11/15/19
BOFA
11/15/19
NO CHANGE
Target $160
BOFA
Buy
Roku price target raised to $160 from $150 at BofA/Merrill
BofA/Merrill analyst Ziv Israel noted that Roku (ROKU) announced a variety of Black Friday offers and discounts on Roku streaming devices, content promotions, and the temporary availability of the Roku SE streaming player exclusively at Walmart (WMT). The company also announced three new smart TV models sold under the Walmart house brand that he estimates are currently priced at about half of TVs with similar attributes. The lower device average selling prices and new smart TV offerings provide a "solid setup for outsized Q4 account growth," contends Israel, who reiterates a Buy rating and raised his price target to $160 on Roku shares.
11/07/19
GUGG
11/07/19
NO CHANGE
Target $150
GUGG
Buy
Roku price target lowered to $150 from $170 at Guggenheim
Guggenheim analyst Michael Morris lowered his price target on Roku shares to $150 from $170 after the company reported strong unit and revenue growth trends in both its Platform and Product segments in the third quarter but posted active account growth that was below consensus and had outperformance that "lagged historical beats." Also, Roku's guidance ex-acquisitions implies slower growth than he had anticipated, said Morris, who keeps a Buy rating on the stock but lowered his multi-year gross profit estimates by about 10%.
12/02/19
MSCO
12/02/19
DOWNGRADE
Target $110
MSCO
Underweight
Morgan Stanley downgrades Roku to Underweight after 400% year-to-date rally
Morgan Stanley analyst Benjamin Swinburne downgraded Roku to Underweight from Equal Weight with a price target of $110, up from $100. The shares closed Friday down $1.27 to $160.37. Roku continues to execute a "sound strategy" to capitalize on the shift to streaming, but there are risks to growth expectations not reflected in current valuation levels, Swinburne tells investors in a research note. Specifically, he thinks the company's revenue and gross profit growth could slow "meaningfully" in 2020, leading to multiple compression. Swinburne is bullish on Roku's growth prospects, but he notes the shares are up over 400% year-to-date due to rising estimates and overall exuberance over all things streaming. As a result, the stock's risk/reward is skewed to the downside, contends the analyst. He points out that Roku's valuation levels have surged past digital media players and even past high-growth software-as-a-service companies.
SPLK Splunk
$149.24

-1.67 (-1.11%)

11/22/19
MSCO
11/22/19
NO CHANGE
Target $169
MSCO
Overweight
Splunk providing better visibility with new metrics, says Morgan Stanley
Morgan Stanley analyst Keith Weiss said the bounce back in current RPO bookings at Splunk in Q3 speak to the strength in its core business while the company beginning to provide a total annual recurring revenue, or ARR, metric should give investors a clearer picture of underlying growth. The company's FY23 target of about $1B in operating cash flow should also help investors see through the near-term negative impacts of shortening invoice duration, added Weiss, who keeps an Overweight rating on Splunk shares with a price target of $169.
11/22/19
DADA
11/22/19
NO CHANGE
Target $160
DADA
Buy
Splunk price target raised to $160 from $150 at DA Davidson
DA Davidson analyst Andrew Nowinski raised his price target on Splunk to $160 and kept his Buy rating after its "strong" Q3 results and "more importantly" a 53% increased in annualized recurring revenue. The analyst sees this metric as important in gauging the health of a SaaS-based company and sees its rate of growth accelerating, reflecting Splunk's market-leading position and the impact of recent acquisitions.
12/02/19
GSCO
12/02/19
UPGRADE
Target $180
GSCO
Buy
Splunk upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Christopher Merwin upgraded ReneSola to Buy from Neutral with a price target of $180, up from $147. The shares closed Friday down $1.78 to $149.22. After a "strong" fiscal Q3 report, the analyst sees "several catalysts" for Splunk shares to positively re-rate over the next 12 months. These include a new pricing model that decouples revenue from indexed log volume, newly-reported annual recurring revenue growth, and "de-risked" cash flow expectations through fiscal 2023. For a company that is growing annual recurring revenue over 50%, and should continue to grow at least mid-40% through next year per management guidance, Splunk's current valuation of eight-times 2020 sales is "undemanding," Merwin tells investors in a research note.
11/26/19
JMPS
11/26/19
NO CHANGE
Target $155
JMPS
Outperform
Splunk price target raised to $155 from $135 at JMP Securities
JMP Securities analyst Erik Suppiger raised his price target on Splunk to $155 and kept his Outperform rating after its Q3 earnings beat and a 28% increase in billings along with its FY20 guidance range. The analyst maintains his view that Splunk is undervalued, currently trading at an enterprise value to expected 2021 revenue multiple of 6.2-times.
EYEG EyeGate
$7.83

0.105 (1.36%)

EVFM Evofem
$6.08

0.02 (0.33%)

01/07/19
HCWC
01/07/19
NO CHANGE
Target $12.5
HCWC
Buy
Evofem price target raised to $12.50 from $11 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Evofem Biosciences to $12.50 after the Ampower pivotal trial met its primary endpoint. The results demonstrate that when Amphora is used as directed, the efficacy in which women can have confidence is similar to other frequently-used contraceptive methods, says the analyst. He reiterates a Buy rating on Evofem.
10/16/19
CANT
10/16/19
INITIATION
Target $9
CANT
Overweight
Evofem assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen assumed coverage of Evofem with an Overweight rating and $9 price target. The market opportunity for the company's Amphora is underappreciated, Chen tells investors in a research note. Amphora could be: a first-in-class hormone-free birth control that also improves sexual satisfaction, says the analyst. She believes now is a good time to take another look at Evofem shares ahead of the Phase 2b trial results in November.
04/12/19
OPCO
04/12/19
NO CHANGE
Target $11
OPCO
Outperform
Evofem price target raised to $11 from $9 at Oppenheimer
Oppenheimer analyst Leland Gershell raised his price target for Evofem Biosciences (EVFM) to $11 from $9 following yesterday's announcement of the securities purchase agreement with PDL BioPharma (PDLI), which he says cures a significant financing overhang on favorable terms, mitigates uncertainty around U.S. commercial economics, and provides validation by a well-regarded strategic healthcare investor. He maintains an Outperform rating.
04/12/19
CANT
04/12/19
NO CHANGE
Target $9
CANT
Overweight
Evofem financing removes near-term capital concerns, says Cantor Fitzgerald
Cantor Fitzgerald analyst Matthew Lillis believes Evofem Biosciences' (EVFM) financing agreement for up to $80M, including a strategic investment from PDL BioPharma (PDLI), removes near-term capital concerns. Further, it positions Evofem well to execute other pieces of its long-term financing strategy, which may involve sources of non-dilutive capital that could further benefit shareholders, Lillis tells investors in a research note. He reiterates an Overweight rating on the shares with a $9 price target.
AVAV AeroVironment
$61.39

-0.51 (-0.82%)

11/20/19
PIPR
11/20/19
NO CHANGE
Target $76
PIPR
Overweight
AeroVironment should modestly exceed Q2 expectations, says Piper Jaffray
Piper Jaffray analyst Troy Jensen expects AeroVironment to modestly exceed fiscal Q2 expectations when reporting on December 3. While the analyst believes first half of fiscal 2020 exceeded the company's internal plans, he thinks management will reiterate fiscal 2020 guidance, making the second half "easier" given the strength in the first half. AeroVironment will benefit as U.S. defense budgets shift toward unmanned aircraft and its international sales should grow even faster than domestic, Jensen tells investors in a pre-earnings research note. He reiterates an Overweight rating on the shares with a $76 price target.
12/02/19
BARD
12/02/19
UPGRADE
Target $81
BARD
Outperform
AeroVironment upgraded to Outperform from Neutral at Baird
Baird analyst Peter Arment upgraded AeroVironment to Outperform from Neutral with an $81 price target.
12/02/19
BARD
12/02/19
UPGRADE
Target $81
BARD
Outperform
AeroVironment upgraded to Outperform at Baird
Baird analyst Peter Arment upgraded AeroVironment to Outperform from Neutral. The analyst expects solid Q2 results tomorrow and believes the outlook for 2020 should be at least maintained with potential for upside despite the lingering Continuing Resolution (CR) reflecting a favorable bookings momentum. He also said the recent pullback has made its valuation more reasonable. Arment raised his price target to $81 from $65 on AeroVironment shares.
10/16/19
PIPR
10/16/19
UPGRADE
Target $76
PIPR
Overweight
AeroVironment upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Troy Jensen upgraded AeroVironment to Overweight from Neutral with a price target of $76, up from $66. The stock closed Tuesday down 10c to $57.06. The recent pullback in the shares has created a more compelling entry point, Jensen tells investors in a research note. The analyst continues to believe AeroVironment will benefit as U.S. defense budgets shift more toward unmanned aircraft. Further, the company's international defense sales should grow even faster than domestic sales, given its recent focus on international expansion, adds Jensen. He says AeroVironment has "solid visibility" for the remainder of fiscal 2020 with 75% of its guidance already booked or in backlog.
MDR McDermott
$0.80

-0.0069 (-0.86%)

11/05/19
SBSH
11/05/19
NO CHANGE
Target $1.6
SBSH
Neutral
McDermott bankruptcy risk is rising, Citi says, while cutting target to $1.60
Citi analyst Andrew Kaplowitz lowered his price target for McDermott International to $1.60 from $2.00 and keeps a Neutral rating on the shares. The stock closed yesterday up 6c to $1.76. The company's risks continue to rise following its "disappointing" Q3 results, Kaplowitz tells investors in a research note. With continued deterioration in cash, McDermott's bankruptcy risk is rising as the company stated in its quarterly filing that "there is substantial doubt regarding our ability to continue as a going concern," the analyst points out. While Kaplowitz continues to see value in McDermott' technology asset and believes it can be sold for $2.5B through competitive bidding, he sees rising uncertainty surrounding the company's future operation.
09/20/19
FBCO
09/20/19
NO CHANGE
Target $7
FBCO
Neutral
McDermott's plans to sell Lummus 'a last resort,' says Credit Suisse
Credit Suisse analyst Jamie Cook says McDermott's announcement that it will explore selling its Lummus technology business was considered "a last resort," but was "unfortunately needed" to improve the balance sheet. Cook, who maintains a Neutral rating and $7.00 price target, says she believes McDermott would prefer to retain some ownership in order to retain rights to be the first bidder on the EPC business if possible. She feels a transaction could occur "quickly," given the asset was already on the market recently and says she believes the stock should rally on this news given the dramatic sell off this week and that management is not considering chapter 11.
09/19/19
SBSH
09/19/19
NO CHANGE
Target $7
SBSH
Neutral
Citi sees working capital unwind as 'legitimate risk' for McDermott
Shares of McDermott dropped 63% yesterday following news that the company hired turnaround firm AlixPartners for "strategic and operational advice." Low liquidity, high leverage, and lingering headwinds associated with legacy CB&I-related projects pose elevated risk for the company, Citi analyst Andrew Kaplowitz tells investors in a research note. The analyst admits that he does not know what's causing McDermott to turn to AlixPartners. He sees a "wide range of possibilities with little visibility to near-term outcomes," which leads to his continued Neutral rating on the shares. McDermott has a "considerable amount of good assets" that are saleable and customers have an incentive to see the company succeed, says Kaplowitz. However, a working capital unwind is now a "legitimate risk" and it may be harder for McDermott to win work at this point, adds the analyst.
09/11/19
SBSH
09/11/19
NO CHANGE
Target $7
SBSH
Neutral
McDermott price target lowered to $7 from $11 at Citi
Citi analyst Andrew Kaplowitz lowered his price target for McDermott to $7 from $11 while keeping a Neutral rating on the shares. While the analyst sees "some light at the end of the tunnel" for the company on its two "troublesome" liquefied natural gas projects and believes the negative estimate revisions for CBI Legacy work may be behind the company, he says he can't rule out "further project-related noise." Further, McDermott's balance sheet is still relatively levered and some uncertainty regarding the timing of asset sales remains, Kaplowitz tells investors in a research note.
LXRX Lexicon
$3.54

-0.01 (-0.28%)

09/11/19
GABE
09/11/19
UPGRADE
GABE
Buy
Lexicon upgraded to Buy at Gabelli, says agreement a 'clean break'
Gabelli analyst Kevin Kedra upgraded Lexicon to Buy from Hold after the company said Sanofi (SNY) has finalized its termination of the sotagliflozin collaboration with a $260M payment, citing valuation and increased optimism for sotagliflozin's future. In a research note to investors, Kedra says the agreement is a "clean break" from Sanofi while also modestly extending Lexicon's cash runway, and expects Lexicon to have enough cash to support operations into 2021.
09/11/19
GABE
09/11/19
UPGRADE
GABE
Buy
Lexicon upgraded to Buy from Hold at Gabelli
09/11/19
SBSH
09/11/19
NO CHANGE
Target $3
SBSH
Buy
Lexicon settlement with Sanofi removes overhang, says Citi
Citi analyst Yigal Nochomovitz believes Lexicon Pharmaceuticals' (LXRX) settlement with Sanofi (SNY) removes an overhang and that the company's cash runway "may increase modestly." However, the funds are largely already spoken for with respect to continued funding of the core Phase 3 trials in n type 2 diabetes and the outcomes trials, Nochomovitz tells investors in a research note. The analyst keeps a Buy rating on Lexicon shares with a $3 price target.
11/08/19
SBSH
11/08/19
DOWNGRADE
Target $4
SBSH
Neutral
Lexicon downgraded to Neutral from Buy at Citi
Citi analyst Yigal Nochomovitz downgraded Lexicon Pharmaceuticals to Neutral from Buy with a price target of $4, up from $3. The analyst says he struggles to recommend the stock at the current valuation until greater clarity on a favorable path forward for sotagliflozin in type 1 diabetes is obtained. Lexicon announced that it filed a formal dispute to the FDA Office of New Drugs appealing the Complete Repose Letter issued for sotagliflozin. The rate of success for these resolutions is around 15% to 20%, Nochomovitz tells investors in a research note.
TDOC Teladoc
$83.65

-2.19 (-2.55%)

12/02/19
RHCO
12/02/19
DOWNGRADE
Target $80
RHCO
Hold
Teladoc downgraded to Hold from Buy at SunTrust
SunTrust analyst Alexander Draper downgraded Teladoc to Hold from Buy with an unchanged $80 price target. The analyst notes that the stock is up 69% year-to-date and its enterprise value to sales multiple has reached a 9-turn premium to its 5-year historical average. Draper adds that while that valuation is in-line with the similarly growing software companies, he sees "limited opportunities" for continued multiple expansion and believes that the Street consensus is overestimating the revenue tailwinds of "recent wins and macro backdrop".
11/25/19
11/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Magellan Midstream (MMP) initiated with a Buy at Goldman Sachs. 2. Azure Power (AZRE) initiated with a Buy at Jefferies. 3. Teladoc (TDOC) initiated with a Hold at Stifel. 4. Rapt Therapeutics (RAPT) initiated with a Buy at UBS as well as an Outperform at Wells Fargo and BMO Capital. 5. Qiwi (QIWI) initiated with a Buy at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/02/19
RHCO
12/02/19
DOWNGRADE
Target $80
RHCO
Hold
Teladoc downgraded to Hold from Buy at SunTrust
SunTrust analyst Alexander Draper downgraded Teladoc to Hold from Buy with an $80 price target.
11/25/19
STFL
11/25/19
INITIATION
Target $83
STFL
Hold
Teladoc initiated with a Hold at Stifel
Stifel analyst David Grossman initiated coverage of Teladoc Health with a Hold rating and $83 price target. The analyst believes the company's near-term revenue growth targets are reasonable, but his neutral rating reflects valuation and "some lack of visibility on how margins evolve over time." He prefers an entry point with a more attractive risk/reward profile.
AQMS Aqua Metals
$1.34

-0.025 (-1.83%)

05/15/19
OPCO
05/15/19
NO CHANGE
Target $9
OPCO
Outperform
Aqua Metals price target lowered to $9 from $14 at Oppenheimer
Oppenheimer analyst Colin Rusch lowered his price target for Aqua Metals to $9 from $14 on increased share count, higher operating expenses and a slower revenue ramp as it shifts to equipment and licensing revenue for growth. The analyst notes that the company posted a wider than expected loss for the quarter while shoring up the balance sheet with an equity raise. He reiterates an Outperform rating on the shares.
ADT ADT Inc.
$9.25

-0.23 (-2.43%)

05/13/19
05/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Deere (DE) and Titan Machinery (TITN) downgraded to Neutral from Outperform at Baird. 2. Boot Barn (BOOT) downgraded to Hold from Buy at Pivotal Research with analyst Mitch Kummetz saying he sees a less favorable risk/reward at current share levels heading into the company's results on May 16. He does not see enough room for upside to his estimates, mainly because he believes oil and gas employment is becoming a "diminishing tailwind." 3. Shopify (SHOP) downgraded to Neutral from Buy at Guggenheim with analyst Ken Wong saying he sees upside potential as limited given the stock's current valuation, which he notes has now passed previous peak levels. 4. ADT Inc. (ADT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Toni Kaplan saying she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. 5. 51job (JOBS) downgraded to Neutral from Buy at Citi with analyst Alicia Yap saying she believes weakening operating metrics, such as a faster rate of decline for active employer count and slower rate of growth of ARPU, may be signals of challenges for online recruitment revenue growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/02/19
BOFA
12/02/19
DOWNGRADE
BOFA
Neutral
ADT Inc. downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill downgraded ADT Inc. to Neutral from Buy.
12/02/19
BOFA
12/02/19
DOWNGRADE
Target $9.5
BOFA
Neutral
ADT Inc. downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Gary Bisbee downgraded ADT Inc. to Neutral from Buy with a $9.50 price target. The analyst notes that while the valuation on the stock is "far from demanding" and investment sentiment in the name is still "subdued", he also sees "few catalysts" to warrant sustained outperformance. Bisbee believes that the risk-reward on ADT is now "more balanced" at current levels, forecasting "flattish" revenue along with slightly lower annualized profits and cash flow in 2020.
05/13/19
MSCO
05/13/19
DOWNGRADE
Target $7
MSCO
Equal Weight
ADT Inc. downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Toni Kaplan downgraded ADT Inc. (ADT) to Equal Weight from Overweight as she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. The survey showed homeowners seem as inclined to buy DIY systems as ADT systems, that more ADT customers switched to DIY providers than she would have expected and that measure of brand preference for Amazon's (AMZN) Ring and Google's (GOOG) Nest were higher than for ADT, Kaplan explains. Given that the survey leads her to fear ADT may find it difficult to defend its market share, Kaplan lowered her price target on the stock to $7 from $9.

TODAY'S FREE FLY STORIES

FITB

Fifth Third

$30.24

0.365 (1.22%)

, CSCO

Cisco

$43.83

0.29 (0.67%)

18:37
12/06/19
12/06
18:37
12/06/19
18:37
Hot Stocks
Fifth Third issues statement on temporary network outage »

Fifth Third Bank (FITB)…

FITB

Fifth Third

$30.24

0.365 (1.22%)

CSCO

Cisco

$43.83

0.29 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 08

    Jan

  • 12

    Feb

STML

Stemline

$10.33

0.5 (5.09%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

18:33
12/06/19
12/06
18:33
12/06/19
18:33
Hot Stocks
Stemline names Robert Francomano as Chief Commercial Officer »

Most recently, Francomano…

STML

Stemline

$10.33

0.5 (5.09%)

PFE

Pfizer

$38.29

0.26 (0.68%)

GSK

GlaxoSmithKline

$45.51

0.29 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

GOL

Gol Linhas

$17.39

1.07 (6.56%)

18:31
12/06/19
12/06
18:31
12/06/19
18:31
Hot Stocks
Gol Linhas announces preliminary traffic figures for November »

GOL's domestic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVB

Navidea

$0.97

0.07 (7.78%)

18:25
12/06/19
12/06
18:25
12/06/19
18:25
Syndicate
Navidea announces $1.9M private placement »

Navidea announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFC

Ellington Financial

$18.22

0.09 (0.50%)

18:23
12/06/19
12/06
18:23
12/06/19
18:23
Hot Stocks
Ellington Financial reports estimated book value per share $18.51 on November 30 »

This estimate includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOOT

Boot Barn

$41.93

0.81 (1.97%)

18:22
12/06/19
12/06
18:22
12/06/19
18:22
Hot Stocks
Boot Barn CEO: More than 80% of our business is in the store »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$9.24

0.1 (1.09%)

18:18
12/06/19
12/06
18:18
12/06/19
18:18
Hot Stocks
Ericsson to pay over $1B to settle FCPA case »

Ericsson has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GLD

SPDR Gold Shares

$137.59

-1.42 (-1.02%)

17:55
12/06/19
12/06
17:55
12/06/19
17:55
Hot Stocks
SPDR Gold Shares holdings fall to 886.23MT from 888.57MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PICO

PICO Holdings

$10.81

0.31 (2.95%)

17:45
12/06/19
12/06
17:45
12/06/19
17:45
Hot Stocks
PICO Holdings sells long-term storage credits for $8.7M in Arizona »

PICO Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QHC

Quorum Health

$0.95

0.0522 (5.81%)

17:31
12/06/19
12/06
17:31
12/06/19
17:31
Hot Stocks
Quorum Health receives NYSE continued listing standard notice »

Quorum Health Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:30
12/06/19
12/06
17:30
12/06/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Support.com »

Support.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXRX

Baudax Bio

$6.69

0.34 (5.35%)

17:29
12/06/19
12/06
17:29
12/06/19
17:29
Syndicate
Breaking Syndicate news story on Baudax Bio »

Baudax Bio files $125M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

LMT

Lockheed Martin

$387.10

1.175 (0.30%)

17:25
12/06/19
12/06
17:25
12/06/19
17:25
Hot Stocks
Lockheed Martin awarded $153.39M Navy contract modification »

Lockheed Martin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENV

Envestnet

$71.72

1.27 (1.80%)

17:23
12/06/19
12/06
17:23
12/06/19
17:23
Syndicate
Breaking Syndicate news story on Envestnet »

Envestnet files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$344.79

0.4 (0.12%)

17:20
12/06/19
12/06
17:20
12/06/19
17:20
Hot Stocks
Northrop Grumman awarded $189M Navy contract modification »

Northrop Grumman was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:03
12/06/19
12/06
17:03
12/06/19
17:03
Hot Stocks
Support.com announces special distribution of $1.00 per share »

The record date for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:01
12/06/19
12/06
17:01
12/06/19
17:01
Hot Stocks
Breaking Hot Stocks news story on Support.com »

Support.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RZLT

Rezolute

$0.00

(0.00%)

17:00
12/06/19
12/06
17:00
12/06/19
17:00
Syndicate
Breaking Syndicate news story on Rezolute »

Rezolute files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

16:58
12/06/19
12/06
16:58
12/06/19
16:58
Periodicals
U.S. mulls putting Amazon foreign sites on 'Notorious Markets' list, WSJ says »

The Trump administration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

16:55
12/06/19
12/06
16:55
12/06/19
16:55
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

IMH

IMPAC Mortgage

$5.63

-0.01 (-0.18%)

16:54
12/06/19
12/06
16:54
12/06/19
16:54
Syndicate
Breaking Syndicate news story on IMPAC Mortgage »

IMPAC Mortgage files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALEC

Alector

$19.74

0.33 (1.70%)

16:32
12/06/19
12/06
16:32
12/06/19
16:32
Hot Stocks
Alector reports Phase 1 safety, biomaker data on AL002 »

Alector reported safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATAX

America First Multifamily Investors

$7.58

0.125 (1.68%)

16:31
12/06/19
12/06
16:31
12/06/19
16:31
Hot Stocks
America First Multifamily Investors CFO Craig Allen to retire »

On December 2,Craig Allen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
12/06/19
12/06
16:30
12/06/19
16:30
Options
Preliminary option volume of 20.4M today »

Preliminary option volume…

PNM

PNM Resources

$48.77

-0.06 (-0.12%)

16:29
12/06/19
12/06
16:29
12/06/19
16:29
Hot Stocks
PNM Resources raises quarterly dividend 6% to 30.75c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.